Risk stratification of adults with congenital heart disease during the COVID-19 pandemic: insights from a multinational survey among European experts.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
04 2021
Historique:
received: 18 09 2020
revised: 09 03 2021
accepted: 22 03 2021
entrez: 22 4 2021
pubmed: 23 4 2021
medline: 8 5 2021
Statut: ppublish

Résumé

Adults with congenital heart disease (ACHD) may be at a higher risk of a fatal outcome in case of COVID-19. Current risk stratification among these patients relies on personal experience and extrapolation from patients with acquired heart disease. We aimed to provide an expert view on risk stratification while awaiting results from observational studies. This study was an initiative of the EPOCH (European Collaboration for Prospective Outcome Research in Congenital Heart disease). Among nine European countries (Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Spain and Switzerland), 24 experts from 23 tertiary ACHD centres participated in the survey. ACHD experts were asked to identify ACHD-specific COVID-19 risk factors from a list of potential outcome predictors and to estimate the risk of adverse COVID-19 outcomes in seven commonly seen patient scenarios. 82% of participants did not consider all ACHD patients at risk of COVID-19 related complications. There was a consensus on pulmonary arterial hypertension, Fontan physiology and cyanotic heart disease as risk factors for adverse outcomes. Among different ACHD scenarios, a patient with Eisenmenger syndrome was considered to be at the highest risk. There was a marked variability in risk estimation among the other potential outcome predictors and ACHD scenarios. Pulmonary arterial hypertension, Fontan palliation and cyanotic heart disease were widely considered as risk factors for poor outcome in COVID-19. However, there was a marked disparity in risk estimation for other clinical scenarios. We are in urgent need of outcome studies in ACHD suffering from COVID-19.

Identifiants

pubmed: 33883228
pii: openhrt-2020-001455
doi: 10.1136/openhrt-2020-001455
pmc: PMC8061557
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Werner Budts (W)
Massimo Chessa (M)
Julie De Backer (J)
Gerhard Diller (G)
Rocío García Orta (RG)
María Elvira (M)
Rodríguez-Monte Garrido-Lestache (RM)
Elvira Ana González (EA)
Pablo Meras (P)
Berta Miranda (B)
Marielle Morissens (M)
Agnes Pasquet (A)
Joaquin Rueda Soriano (JR)
Annette Schophuus Jensen (AS)
Oktay Tutare (O)
Annemien van den Bosch (AVD)
Heleen van der Zwaan (HV)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Circulation. 2015 Dec 1;132(22):2118-25
pubmed: 26369353
J Am Heart Assoc. 2020 Jun 16;9(12):e017224
pubmed: 32441586
Eur Heart J. 2020 Dec 12;:
pubmed: 33313664
Congenit Heart Dis. 2015 Mar-Apr;10(2):117-27
pubmed: 25043406
Swiss Med Wkly. 2017 Nov 09;147:w14519
pubmed: 29120021
Rev Esp Cardiol (Engl Ed). 2020 Oct;73(10):804-811
pubmed: 32249097
Heart. 2020 Sep;106(17):1302-1309
pubmed: 32522822

Auteurs

Francisco Javier Ruperti-Repilado (FJ)

Center for Congenital Heart Disease, Cardiology, Inselspital University Hospital Bern, University of Bern, Bern, Switzerland.

Daniel Tobler (D)

Division of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.

Matthias Greutmann (M)

University Heart Centre Zurich, Department of Cardiology, University of Zurich, Zurich, Switzerland.

Judith Bouchardy (J)

Cardiovascular Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Service de Cardiologie, University Hospital of Geneva, Geneve, Switzerland.

Magalie Ladouceur (M)

Adult Congenital Heart Disease Unit, Centre de Référence des Malformations Cardiaques Congénitales Complexes, M3C, Inserm U970, Paris Centre de Recherche Cardiovasculaire, Hôpital Europeen Georges-Pompidou Pôle Cardio-vasculaire Rénal Métabolique, Paris, France.

Laura Dos-Subira (L)

Unitat Integrada de Cardiopaties Congènites de l'Adolescent i l'Adult, Vall d'Hebron-Sant Pau, Vall d'Hebron University Hospital. Vall d'Hebron Barcelona Hospital Campus and CIBERCV, Barcelona, Spain.

Pastora Gallego (P)

Adult Congenital Heart Disease Unit, Instituto de BioMedicina de Sevilla (IBIS) and CIBERCV, Virgen del Rocio University Hospital Cardiology and Cardiovascular Surgery Service, Sevilla, Spain.

Harald Gabriel (H)

Adult Congenital Heart Disease Centre, Medical University of Vienna, Wien, Austria.

Berto Bouma (B)

Department of Cardiology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands.

Markus Schwerzmann (M)

Center for Congenital Heart Disease, Cardiology, Inselspital University Hospital Bern, University of Bern, Bern, Switzerland markus.schwerzmann@insel.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH